Abstract
Introduction: Hepatocellular carcinoma (HCC) carcinogenesis is not yet fully known. Insulin-like growth factor-1 receptor (IGF-1R) can translocate to the nucleus and modulate cellular growth, possibly participating in HCC development and aggressiveness. This study aimed to evaluate the immunoexpression of IGF-1R in HCC, the cellular compartment involved, and its association with clinicopathological parameters and clinical outcomes. Methods: Liver specimens from 111 HCC patients who underwent liver transplantation or partial surgical resections at a Brazilian referral hospital center were studied. IGF-1R expression was determined by immunohistochemistry, clinical data were collected from medical records, and pathological parameters were obtained from path review. Results: IGF-1R nuclear expression was higher in the tumor than in the adjacent cirrhosis (p < 0.001). The odds of IGF-1R expression in the nucleus compared to the membrane are lower in the cirrhosis condition than in the tumor, suggesting an increase in the prevalence of nucleus expression relative to the membrane from cirrhosis to tumor. There was an association between IGF-1R nuclear expression in HCC and the moderate/poor grade of histologic differentiation (p < 0.001). However, long-term clinical outcomes were not associated with IGF-1R nuclear expression. Conclusion: The data presented here suggest the role of IGF-1R in HCC progression and carcinogenesis as its expression increases in the nucleus relative to the membrane, from cirrhosis to tumor, and it was associated with a poorer differentiated tumor grade. Further research is awaited to fully understand the mechanisms underlying this association.
Journal Section:
Clinical Study
References
1.
Nagtegaal
ID
, Odze
RD
, Klimstra
D
, Paradis
V
, Rugge
M
, Schirmacher
P
et al. The 2019 WHO classification of tumours of the digestive system
. Histopathology
. 2020
;76
(2
):182
–8
.2.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
.3.
Zhang
Z
, Lei
B
, Chai
W
, Liu
R
, Li
T
. Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma
. Medicine
. 2019
;98
(44
):e17680
.4.
Bruix
J
, Gores
GJ
, Mazzaferro
V
. Hepatocellular carcinoma: clinical frontiers and perspectives
. Gut
. 2014
;63
(5
):844
–55
.5.
Tian
L-Y
, Smit
DJ
, Jücker
M
. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism
. Int J Mol Sci
. 2023
;24
(3
):2652
.6.
Ferrín
G
, Guerrero
M
, Amado
V
, Rodríguez-Perálvarez
M
, De la Mata
M
. Activation of mTOR signaling pathway in hepatocellular carcinoma
. Int J Mol Sci
. 2020
;21
(4
):1266
.7.
Bie
C
, Chen
Y
, Tang
H
, Li
Q
, Zhong
L
, Peng
X
et al. Insulin-like growth factor 1 receptor drives hepatocellular carcinoma growth and invasion by activating stat3-midkine-stat3 loop
. Dig Dis Sci
. 2022
;67
(2
):569
–84
.8.
Chun
YS
, Huang
M
, Rink
L
, Von Mehren
M
. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study
. World J Surg Oncol
. 2014
;12
(1
):231
–7
.9.
Kudo
M
. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma
. Dig Dis
. 2011
;29
(3
):289
–302
.10.
Bowers
LW
, Rossi
EL
, O’Flanagan
CH
, deGraffenried
LA
, Hursting
SD
. The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer Link
. Front Endocrinol
. 2015
;6
:77
.11.
Adamek
A
, Kasprzak
A
. Insulin-like growth factor (IGF) system in liver diseases
. Int J Mol Sci
. 2018
;19
(5
):1308
.12.
Hua
H
, Kong
Q
, Yin
J
, Zhang
J
, Jiang
Y
. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
. J Hematol Oncol
. 2020
;13
(1
):64
–17
.13.
Scharf
J-G
, Dombrowski
F
, Ramadori
G
. The IGF axis and hepatocarcinogenesis
. Mol Pathol
. 2001
;54
(3
):138
–44
.14.
Aleksic
T
, Chitnis
MM
, Perestenko
OV
, Gao
S
, Thomas
PH
, Turner
GD
et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells
. Cancer Res
. 2010
;70
(16
):6412
–9
.15.
Zhang
Z
, Zhang
Y
, Lao
S
, Qiu
J
, Pan
Z
, Feng
X
. The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer
. BMC Cancer
. 2022
;22
(1
):855
–11
.16.
Zhao
J
, Shi
X
, Wang
T
, Ying
C
, He
S
, Chen
Y
. The prognostic and clinicopathological significance of IGF-1R in NSCLC: a meta-analysis
. Cell Physiol Biochem
. 2017
;43
(2
):697
–704
.17.
Bieghs
L
, Johnsen
HE
, Maes
K
, Menu
E
, Van Valckenborgh
E
, Overgaard
MT
et al. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
. Oncotarget
. 2016
;7
(30
):48732
–52
.18.
De Minicis
S
, Marzioni
M
, Benedetti
A
, Svegliati-Baroni
G
. New insights in hepatocellular carcinoma: from bench to bedside
. Ann Transl Med
. 2013
;1
(2
):15
.19.
Yan
X-D
, Yao
M
, Wang
L
, Zhang
H-J
, Yan
M-J
, Gu
X
et al. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation
. Available from: http://wwwwjgnetcom/2013.20.
Warsito
D
, Sjöström
S
, Andersson
S
, Larsson
O
, Sehat
B
. Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF
. EMBO Rep
. 2012
;13
(3
):244
–50
.21.
Diniz
PHC
, Silva
SDC
, Vidigal
PVT
, Xavier
MAP
, Lima
CX
, Faria
LC
et al. Expression of MAPK and PI3K/AKT/mTOR proteins according to the chronic liver disease etiology in hepatocellular carcinoma
. J Oncol
. 2020
;2020
:4609360
.22.
Wei
Y
, Liu
D
, Zhou
F
, Ge
Y
, Xu
J
, Yun
X
et al. Identification of β-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell
. J Hepatol
. 2008
;49
(6
):1029
–37
.23.
Liu
H
, Xu
L
, He
H
, Zhu
Y
, Liu
J
, Wang
S
et al. Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein
. Cancer Sci
. 2012
;103
(12
):2072
–81
.24.
Sivasudhan
E
, Blake
N
, Lu
Z
, Meng
J
, Rong
R
. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review
. Cells
. 2022
;11
(4
):741
.25.
Kim
S-O
, Park
JG
, Lee
YI
. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product
. Cancer Res
. 1996
;56
(16
):3831
–6
.26.
Tamura
S
, Kato
T
, Berho
M
, Misiakos
EP
, O’Brien
C
, Reddy
KR
. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation
. Arch Surg
. 2001
;136
(1
):25
–30
; discussion 31.27.
Nevola
R
, Ruocco
R
, Criscuolo
L
, Villani
A
, Alfano
M
, Beccia
D
et alPredictors of early and late hepatocellular carcinoma recurrence
. Available from: http://wwwwjgnetcom/2023.28.
Kang
GH
, Lee
BS
, Lee
ES
, Kim
SH
, Lee
HY
, Kang
DY
. Prognostic significance of p53, mTOR, c-met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma
. Gut Liver
. 2014
;8
(1
):79
–87
.29.
Shinkawa
H
, Tanaka
S
, Kabata
D
, Takemura
S
, Amano
R
, Kimura
K
et al. The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size
. Liver Cancer
. 2021
;10
(5
):461
–72
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
